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ABSTRACT Recent research suggests that women with polycystic ovary syndrome (PCOS) have a higher
risk of asthma. However, the severity of asthma, use of antiasthma medication and effect on fertility have
yet to be investigated.
In a case–control cross-sectional registry study using the Danish National Patient Register and other
Danish registries, asthma prevalence, asthma severity, antiasthma medication use and fertility outcome
were investigated among two groups of women with PCOS (n=1358 and n=17123) and a healthy control
group (n=5340).
Both asthma prevalence (OR 1.45, 95% CI 1.24–1.70) and mean daily inhaled corticosteroid dose were
higher among women with PCOS compared with healthy controls, whereas asthma severity was the same
in women with and without PCOS. Women with PCOS and asthma had more in vitro fertilisation
treatments than women in the control group with asthma, but the numbers of children per woman and
spontaneous abortions were the same.
Women with PCOS have a higher prevalence of asthma and a higher use of inhaled corticosteroids,
whereas asthma severity is the same in women with and without PCOS. Asthma is associated with more
in vitro fertilisation treatments in women with PCOS.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of childbearing
age, with a prevalence of 9–18%. Additionally, up to 69% of women with PCOS do not have a formal
diagnosis, illustrating the likely existence of a large group of women with undiagnosed PCOS [1]. PCOS is
a multifactorial disorder characterised by anovulation, hyperandrogenism, polycystic ovaries, insulin
resistance, obesity, infertility, low-grade systemic inflammation and cardiovascular disease [2, 3].
Asthma is the most common chronic disease among young adults in the industrialised world, affecting
more than 300 million individuals worldwide [4]. Asthma affects 6% of women of childbearing age
and the prevalence increases with obesity [5, 6]. Asthma is characterised by expiratory airflow limitations
with symptoms of wheezing, shortness of breath, chest tightness and cough, with varying symptoms and
intensity over time [4].
As with PCOS, asthma is associated with metabolic syndrome [7], especially noneosinophilic asthma in
obese women [6], and is also associated with a raised level of systemic inflammation [8]. Moreover, PCOS
and asthma are both conditions with a large impact on personal, social and socioeconomic wellbeing,
leading to a decreased quality of life [9, 10].
The association of PCOS and asthma has been investigated in a few studies [11–13]. Women with PCOS
have a significantly higher prevalence of asthma (3% versus 2%), and use significantly more asthma and
allergy medicine, than women without PCOS [13]. The higher prevalence of asthma has been found to
remain significant even after adjustment for body mass index (BMI) and smoking status [12].
Additionally, women with PCOS and asthma are more often admitted to hospital (10.6% versus 4.5%) due
to their asthma and experience a higher prevalence (22.8% versus 14.2%) of respiratory diseases in general
[11]. Impaired fertility is seen in both PCOS and asthma, with a prolonged time to pregnancy [14, 15].
However, little is known with regard to asthma severity among women with PCOS and how asthma affects
the fertility of women suffering from PCOS. The aim of the present study was to investigate the prevalence
of asthma, use of antiasthma medication and severity of asthma among women with PCOS compared with
matched controls, and to explore the association between asthma and fertility among women with PCOS.
Methods
Study design
A case–control cross-sectional registry study was performed, consisting of three female cohorts, with data
extracted in September 2017 (figure 1).
Data sources
The data for this study were extracted and merged from the Danish National Patient Register [16], the
Danish In Vitro Fertilisation (IVF) Register [17], the Danish National Birth Cohort [18] and the Danish
national prescription registries [19]. The unique civil registration number of all the women of the three
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FIGURE 1 Study population. PCOS: polycystic ovary syndrome; COPD: chronic obstructive pulmonary disease.
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groups was used to cross-link data between the different registries. Follow-up on registry data was from
1994 to 2017 (23 years).
Study population
PCOS1 group
The PCOS1 group consisted of 1358 women diagnosed with PCOS according to the Rotterdam criteria [20].
All the women were diagnosed with PCOS by the same specialist in gynaecology and obstetrics at
Copenhagen Fertility Center (Copenhagen, Denmark). A second doctor confirmed the PCOS diagnosis
through medical reports and blood samples. All the women in the PCOS1 group were referred with and
treated for PCOS in private practice. The youngest was born in 2001 and the oldest was born in 1944.
PCOS2 group
The PCOS2 group consisted of 17123 women with the International Classification of Diseases (ICD)-10
diagnosis E28.2 (PCOS) from the Danish National Patient Register. None of the patients from the PCOS1
group were included in the PCOS2 group.
Healthy control group
A total of 5430 non-PCOS women were matched 4:1 with the women of the PCOS1 group on age, sex and
geographical region of Denmark in which they lived in at the age of 15 years (index date). These controls did
not have any of the following diagnoses under ICD-10: E28.2 (PCOS), E28.2C (polycystic ovaries without
anovulation), L68.0 (hirsutism), N91.3 (primary oligomenorrhoea), N91.4 (secondary oligomenorrhoea),
N91.5 (oligomenorrhoea unspecified), N91.0 (primary amenorrhoea), N91.1 (secondary amenorrhoea) or
N91.2 (amenorrhoea unspecified), or under ICD-8: 626.11 (oligomenorrhoea), 626 (amenorrhoea) or 704
(hirsutism).
Age
Women aged 15–45 years at the time of data extraction were included (figure 1).
Asthma diagnosis
Subgroups were defined according to the presence of an asthma diagnosis within the two PCOS groups
and the control group. An observation period of 365 days was used to map the use of antiasthma
medication starting from the date of the first redeemed prescription of medicine from the Anatomical
Therapeutic Chemical (ATC) code R03 group (drugs for obstructive airways disease).
The asthma diagnosis was defined as: redeemed two or more prescriptions of drugs with an ATC code
from the R03 group during the 365 days of observation [21] and/or at least one of the ICD-10 codes for
asthma from the Danish National Patient Register: J45.9 (asthma, unspecified), J45.0 (allergic asthma),
J45.1 (nonallergic asthma), J45.8 (mixed asthma) or J46 (acute severe asthma).
Asthma diagnosis was excluded by the presence of one or more of the following: a diagnosis of chronic
obstructive pulmonary disease (COPD) (ICD-10: J44), ⩾45 years of age (to exclude possible noncoded
COPD patients) and/or the use of medication specific for COPD (roflumilast).
Classification of asthma severity
Asthma severity was classified according to the inhaled corticosteroid (ICS) dose of budesonide (or
budesonide equivalent) from the Global Initiative for Asthma (GINA) guidelines [4]. Data were collected
from the Danish National Patient Register [22]. GINA steps 1–3 (mild to moderate asthma):
⩽400 µg·day−1 budesonide (or budesonide equivalent) in combination with a long-acting β2-agonist
(LABA) or short-acting β2-agonist (SABA), or monotherapy with ICS, or monotherapy with SABA. GINA
steps 4–5 (severe asthma): >400 µg·day−1 budesonide (or budesonide equivalent) and a second controller:
LABA, leukotriene antagonist or theophylline and SABA.
Registries
All Danish citizens have a personal identification number (civil registration number) [23]. This
identification number enables data collection and cross-linking of all public registries used herein. The
number of women receiving IVF cycles was identified using data from the Danish IVF Register [17]. The
numbers of live/still births and singleton/twin births were identified using data from the Danish National
Birth Cohort [18]. Additionally, information on BMI and smoking status was only available for the
women who had a live or still birth (data collected at the eighth week of pregnancy at the first visit to
the general practitioner’s office). Women who stopped smoking in the first trimester of pregnancy were
considered as smokers [24]. The Danish National Patient Register was used to draw information on all
redeemed prescriptions in Danish community pharmacies [19]. The information included the quantity,
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date of redemption, dose and type (ATC code). As all Danish pharmacies are obliged to register all
redeemed prescriptions, the Danish National Patient Register includes 97.5% of all redeemed prescriptions
and is therefore assumed to be comprehensive [22].
Ethics
The Danish Data Protection Agency (2016-41-4561 and 03503 BBH-2015-011) approved the cross-linking
of data. In Denmark, ethical approval is not required for retrospective registry-based studies.
Statistics
The distribution of characteristics was evaluated by mean and standard deviation (range for age) for
continuous explanatory variables, and by frequency and within-group percentage for categorical
explanatory variables. The descriptive difference between groups was assessed by the p-value of pooled
t-tests for continuous variables with equal variance and the Satterthwaite approximation for continuous
variables with unequal variance. For categorical variables, a Chi-squared test was used together with
Fisher’s exact test in the case of antiasthma medication, because of the low numbers involved. Odds ratios
were calculated for the association between asthma (yes/no) and PCOS1/PCOS2 and for asthma and
PCOS1/controls and presented with 95% confidence intervals. All p-values were calculated from two-tailed
tests (p⩽0.05 statistically significant). All analyses were performed using SAS statistical software version
9.4 (SAS Institute, Cary, NC, USA).
Results
The study population consisted of 1358 women in the PCOS1 group, 17123 women in the PCOS2 group
and 5340 in the control group (figure 1).
Asthma and PCOS
There were 266 (22.4%) women with asthma in the PCOS1 group, 3154 (21.9%) women with asthma in
the PCOS2 group and 786 (16.6%) women with asthma in the control group. Among these asthmatic
women, those in the PCOS2 group had a higher BMI and more were smokers than among women with
asthma in the PCOS1 group. In contrast, the BMI of women with asthma in the PCOS1 group was higher
than women with asthma in the control group, which was comprised of more smokers (table 1). SABA
antiasthma medication use was the highest among the three groups, followed by the use of ICSs. Overall,
the use of antiasthma medication was similar between women with asthma in the three groups, although
with a higher use of ICSs in the PCOS1 group compared with the PCOS2 group (table 2).
No difference in the prevalence of asthma was seen between the two PCOS groups. In contrast, a
difference in asthma prevalence between the PCOS1 group and the control group was seen (OR 1.45, 95%
CI 1.24–1.70) (table 1).
TABLE 1 Characteristics of women in the study population meeting the inclusion criteria
PCOS1
group
PCOS2
group
p-value# OR# (95% CI) Control
group
OR¶ (95% CI) p-value¶
Subjects 1186 (5.8) 14415 (70.9) 4729 (23.3)
Age 34 (16–45) 33 (15–45) <0.001 34 (16–45)
BMI available 694 (58.5) 8118 (56.3) 2685 (56.8)
BMI kg·m−2 25.8±5.31 26.89±6.04 <0.001 24.25±4.92 <0.001
Smoker+ 74 (10.4) 1505 (17.7) <0.001 573 (19.6) <0.001
Asthma 266 (22.4) 3154 (21.9) 0.6608 1.03 (0.90–1.19) 786 (16.6) 1.45 (1.24–1.70) <0.001
GINA step within the asthma group 0.8276§ 0.6869§
GINA steps 1–3 (⩽400 µg·daily−1 ICS) 211 (80.5) 2464 (79.6) 608 (78.8)
Dose ICS µg·day−1 148±107.9 139±96.0 0.3423 128±87.9 0.0527
GINA steps 4–5 (>400 µg·daily−1 ICS) 51 (19.5) 617 (19.9) 158 (20.5)
Dose ICS µg·day−1 625±482.5 698±1723.0 0.4527 736±1029.9 0.2975
Data are presented as n (%), n (range) or mean±SD, unless otherwise stated. PCOS: polycystic ovary syndrome; BMI: body mass index; GINA:
Global Initiative for Asthma; ICS: inhaled corticosteroid. BMI and smoking status only available for women who have given birth, data from the
Danish National Birth Cohort. #: difference between PCOS1 and PCOS2; ¶: difference between PCOS1 and control; +: women with data on
smoking status: PCOS1 n=727, PCOS2 n=8336 and control n=2943; §: test for association between GINA steps and patient group. p⩽0.05
statistically significant.
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Among women with asthma, the severity (GINA steps 1–3 or 4–5) of asthma was the same in the two
PCOS groups compared with the control group and so was the mean daily ICS dose. The only difference
seen between the groups was a higher use of ICSs in the PCOS1 group in GINA steps 1–3 compared with
the control group (table 1).
Fertility and PCOS
The number of women receiving IVF treatment and the number of menstrual cycles before achieving
pregnancy within the PCOS1 group were higher compared with the PCOS2 group and the control group.
However, more women in the PCOS2 group had a pregnancy and there was a higher number of children
per woman than in the PCOS1 group. Among the controls, a higher number of children per woman and
more ectopic pregnancies were seen compared with the PCOS1 group; however, women in the PCOS1
group had more twin pregnancies than women in the control group (table 3).
Fertility and PCOS and asthma
Women with asthma in the PCOS1 group received more IVF treatments than women in the control group
and the PCOS2 group. The PCOS1 group also experienced more live births than the PCOS2 group and
TABLE 2 Antiasthma medication and steroids redeemed within the 365-day observation period
in the asthma subpopulation of the study population
PCOS1 group PCOS2 group p-value# Control group p-value¶
Subjects 266 3154 786
SABA 231 (88.2) 2759 (88.9) 0.7125 670 (86.56) 0.5048
ICS 147 (56.1) 1468 (47.3) 0.0062 385 (49.7) 0.0748
ICS/LABA 17 (6.5) 282 (9.1) 0.1556 57 (7.4) 0.6342
LAMA/LABA 0 (0) 13 (0.4) 0.2938 5 (0.7) 0.1922
LABA 12 (4.6) 171 (5.5) 0.5235 54 (7.0) 0.1698
LAMA 0 (0) 4 (0.1) 0.5609 1 (0.1) 0.5605
Biological treatment+ 0 (0) 0 (0) 0 (0)
Oral steroid 6 (2.3) 120 (3.9) 0.1966 31 (4.0) 0.1960
Local steroid 1 (0.40) 4 (0.1) 0.3077 0 (0) 0.0855
Nasal steroid 32 (12.2) 347 (11.2) 0.6122 108 (14.0) 0.4765
Data are presented as n or n (%), unless otherwise stated. PCOS: polycystic ovary syndrome; SABA:
short-acting β2-agonist; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LAMA: long-acting
muscarinic antagonist. #: difference between PCOS1 and PCOS2; ¶: difference between PCOS1 and
control; +: reslizumab, mepolizumab, omalizumab. p⩽0.05 statistically significant.
TABLE 3 Fertility within the study population meeting the inclusion criteria
PCOS1
group
PCOS2
group
p-value# Control
group
p-value¶
Subjects 1186 14415 4729
Receiving IVF treatment 431 (36.3) 4256 (29.5) <0.001 379 (8.0) <0.001
Menstrual cycles before achieving
pregnancy
3.51±2.8 3.07±2.4 <0.001 2.8±2.5 <0.001
Pregnant 829 (69.9) 10462 (72.6) 0.0474 3350 (70.8) 0.5247
Live birth 740 (62.4) 8605 (62.9) 0.7633 2973 (62.9) 0.0682
Children per woman 1.55±0.72 1.59±0.76 0.0361 1.63±0.78 <0.001
Still birth 6 (0.5) 76 (0.5) 0.9222 16 (0.3) 0.3966
Twins 45 (3.8) 437 (3.0) 0.1445 54 (1.1) <0.001
Spontaneous abortions 73 (5.6) 969 (6.7) 0.4521 270 (5.7) 0.5571
Ectopic pregnancies 247 (20.8) 3139 (21.8) 0.4457 1110 (23.5) 0.0527
Data are presented as n, n (%) or mean±SD, unless otherwise stated. PCOS: polycystic ovary syndrome;
IVF: in vitro fertilisation. #: difference between PCOS1 and PCOS2; ¶: difference between PCOS1 and
control. p⩽0.05 statistically significant.
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had more twins than the control group. No differences were found between the other fertility parameters
(table 4).
Discussion
To the best of our knowledge, this is the first study to investigate the severity of asthma based on the use
of antiasthma medication among women with PCOS and the association between asthma and their
fertility. Women with PCOS experience more asthma than women without PCOS. Despite the higher
prevalence of asthma, severity and antiasthma medication use were the same among women with and
without PCOS. In contrast, women with PCOS and asthma received more IVF treatments than women
with asthma alone, but the number of children per woman among the three groups was the same. As seen
with PCOS and asthma, PCOS alone also affects fertility. Women with PCOS received more IVF
treatments and had fewer children per woman than healthy controls. Moreover, women treated for PCOS
in private practice (PCOS1) had fewer children per woman than women treated in public hospitals
(PCOS2) in spite of more IVF treatments, illustrating a possible difference in the severity of PCOS between
these two groups.
Asthma prevalence among women with PCOS
Our study is in line with previous studies demonstrating a higher prevalence of asthma among women
with PCOS. The prevalence in this study of 22%, with asthma defined by the ICD-10 diagnosis or
antiasthma medication use, is among the highest described, whereas a previous Danish registry study
demonstrated a prevalence of only 3% when using the ICD-10 codes J44 (COPD) and J45 (asthma) only [13].
Two Australian studies found 10.6% and 15.2% asthma prevalence among women with PCOS, which is
similar to our findings [11, 12].
Asthma severity and antiasthma treatment
In our study, the prevalence of GINA steps 4–5 asthma, at 20–21%, is in line with earlier epidemiological
studies showing a prevalence of 21–29% [25, 26]. This indicates that the severity of asthma among women
with PCOS is comparable with the general population. However, use of ICSs between the PCOS1 and
PCOS2 groups was different. Furthermore, an earlier Danish registry study of men and women found
45.6% of asthma patients were receiving ICSs and 68.1% of asthma patients were receiving SABAs, in
contrast to a higher general usage of 56.1% receiving ICSs and 88.2% receiving SABAs in our study
population [27]. This may indicate a higher use of antiasthma medicine among young women aged
15–45 years than in the general asthma population.
Fertility and PCOS
In our study, PCOS was associated with impaired fertility, as demonstrated previously [15]. Women with
PCOS received more IVF treatments than the controls. Furthermore, PCOS patients treated in private
practice (PCOS1 group) had more IVF treatments than those treated at public hospitals (PCOS2 group)
(table 3). This may indicate that women treated in private practice have a more severe degree of PCOS
TABLE 4 Fertility in the asthma subpopulation of the study population
PCOS1
group
PCOS2
group
p-value# Control
group
p-value¶
Subjects 266 3154 786
Receiving IVF treatment 93 (35.0) 791 (25.1) 0.0004 72 (9.2) <0.001
Menstrual cycles before achieving
pregnancy
3.34±2.4 3.10±2.5 0.3674 3.04±2.9 0.489
Pregnant 192 (72.2) 2311 (73.3) 0.6956 591 (75.2) 0.3307
Live birth 164 (61.7) 1703 (54.0) 0.016 486 (61.8) 0.9588
Children per women 1.61±0.78 1.58±0.75 0.4031 1.62±0.80 0.8451
Still birth 2 (0.8) 14 (0.4) 0.4801 2 (0.3) 0.2545
Twins 12 (4.5) 97 (3.1) 0.1894 12 (1.5) 0.0048
Spontaneous abortions 16 (6.0) 212 (6.7) 0.6554 52 (6.6) 0.7305
Ectopic pregnancies 56 (21.0) 653 (20.7) 0.8968 208 (26.5) 0.0785
Data are presented as n, n (%) or mean±SD, unless otherwise stated. PCOS: polycystic ovary syndrome;
IVF: in vitro fertilisation. #: difference between PCOS1 and PCOS2; ¶: difference between PCOS1 and
control. p⩽0.05 statistically significant.
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with a lower chance of achieving pregnancy naturally. This severity may be illustrated by the higher
number of menstrual cycles before achieving pregnancy in this group and the fact that these women have
fewer children than women with PCOS treated at public hospitals, in spite of more IVF treatments.
Fertility and asthma and PCOS
Asthma has been shown to prolong the time to pregnancy among women undergoing IVF treatment [14].
Nevertheless, women with asthma achieve the same numbers of pregnancies and live births as healthy
controls [28]. In our study, women with asthma and PCOS received more IVF treatments than women
with asthma alone, illustrating how double disease may lead to an even greater impairment of fertility. Yet,
with the use of IVF treatment, women with PCOS and asthma have the same number of children per
woman as those with asthma alone (table 4). Interestingly, the number of spontaneous abortions was the
same among women with asthma with and without PCOS; this may indicate how the impaired fertility
may be caused by implantation failure or occur even before implantation.
Strength and limitations
The strengths of this registry study lie in the quality of the registries used, which have been validated for
health and health-related welfare research [29]. In addition, all data in the registries were obtained
prospectively and not based on questionnaires or interviews, eliminating the risk of recall bias.
An additional strength of this study is the selection of patients in the PCOS1 group. They were all
evaluated by two doctors and diagnosed by the Rotterdam criteria, thereby minimising the risk of
misclassification.
The identification of women with asthma according to redemption of antiasthma medication ensures
inclusion of all patients treated in private practice and not only those in public hospitals. However, this
also represents a limitation of our study, as the Danish National Patient Register does not show the level of
adherence. Thus, there is a risk of overestimating the medication used and, therefore, the severity of
asthma.
Lastly, we wished to control the possible confounding of obesity (BMI), as obesity is associated with both
asthma [6] and PCOS [7]. This was unfortunately not possible due to the low number of women with
BMI data.
Conclusions
A higher prevalence of asthma is seen among women with PCOS. The severity of asthma and antiasthma
medication use are the same as for women without PCOS. Women with both PCOS and asthma receive
more IVF treatments than women with asthma alone, illustrating a possible additive effect on fertility
impairment. However, women with PCOS and asthma end up with the same number of children per
woman on average as women with asthma alone.
Acknowledgements: A special thanks to Anna von Bülow (Dept of Respiratory Medicine, Bispebjerg Hospital and
Frederiksberg University Hospital, Copenhagen, Denmark) for her great support and help in optimising the method
used herein.
Conflict of interest: None declared.
References
1 March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample
assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 544–551.
2 Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod
Update 2009; 15: 477–488.
3 Duleba AJ, Dokras A. Is PCOS an inflammatory process? Fertil Steril 2012; 97: 7–12.
4 Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2017. http://ginasthma.org/
2017-gina-report-global-strategy-for-asthma-management-and-prevention Date last accessed: August 14, 2017.
5 Kwon HL, Belanger K, Bracken MB. Asthma prevalence among pregnant and childbearing-aged women in the
United States: estimates from national health surveys. Ann Epidemiol 2003; 13: 317–324.
6 Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med
2008; 178: 218–224.
7 Baffi CW, Wood L, Winnica D, et al. Metabolic syndrome and the lung. Chest 2016; 149: 1525–1534.
8 Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 2012; 18: 673–683.
9 Veltman-Verhulst SM, Boivin J, Eijkemans MJC, et al. Emotional distress is a common risk in women with
polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies. Hum Reprod Update 2012; 18:
638–651.
10 Chen H, Gould MK, Blanc PD, et al. Asthma control, severity, and quality of life: quantifying the effect of
uncontrolled disease. J Allergy Clin Immunol 2007; 120: 396–402.
11 Hart R, Doherty DA. The potential implications of a PCOS diagnosis on a woman’s long-term health using data
linkage. J Clin Endocrinol Metab 2015; 100: 911–919.
https://doi.org/10.1183/23120541.00138-2017 7
ASTHMA | L. ZIERAU ET AL.
12 Htet TD, Teede HJ, de Courten B, et al. Asthma in reproductive-aged women with polycystic ovary syndrome and
association with obesity. Eur Respir J 2017; 49: 1601334.
13 Glintborg D, Rubin KH, Nybo M, et al. Morbidity and medicine prescriptions in a nationwide Danish population
of patients diagnosed with polycystic ovary syndrome. Eur J Endocrinol 2015; 172: 627–638.
14 Gade EJ, Thomsen SF, Lindenberg S, et al. Fertility outcomes in asthma: a clinical study of 245 women with
unexplained infertility. Eur Respir J 2016; 47: 1144–1151.
15 Joham AE, Teede HJ, Ranasinha S, et al. Prevalence of infertility and use of fertility treatment in women with
polycystic ovary syndrome: data from a large community-based cohort study. J Women’s Health 2015; 24:
299–307.
16 Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39: Suppl.,
30–33.
17 Andersen AN, Westergaard HB, Olsen J. The Danish In Vitro Fertilisation (IVF) Register. Dan Med Bull 1999; 46:
357–360.
18 Olsen J. The Danish National Birth Cohort – a data source for studying preterm birth. Acta Obstet Gynecol Scand
2005; 84: 539–540.
19 Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997; 44: 445–448.
20 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic
criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–47.
21 Pont LG, van der Werf GT, Denig P, et al. Identifying general practice patients diagnosed with asthma and their
exacerbation episodes from prescribing data. Eur J Clin Pharmacol 2002; 57: 819–825.
22 Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011;
39: 7 Suppl., 38–41.
23 Pedersen CB, Gøtzsche H, Møller JO, et al. The Danish civil registration system. a cohort of eight million persons.
Dan Med Bull 2006; 53: 441–449.
24 Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull 1998; 45: 320–323.
25 Firoozi F, Lemière C, Beauchesne M, et al. Development and validation of database indexes of asthma severity and
control. Thorax 2007; 62: 581–587.
26 Nolte H, Nepper-Christensen S, Backer V. Unawareness and undertreatment of asthma and allergic rhinitis in a
general population. Respir Med 2006; 100: 354–362.
27 von Bülow A, Kriegbaum M, Backer V, et al. The prevalence of severe asthma and low asthma control among
Danish adults. J Allergy Clin Immunol 2014; 2: 759–767.
28 Gade EJ, Thomsen SF, Lindenberg S, et al. Asthma affects time to pregnancy and fertility: a register-based twin
study. Eur Respir J 2014; 43: 1077–1085.
29 Thygesen LC, Ersbøll AK. Danish population-based registers for public health and health-related welfare research:
introduction to the supplement. Scand J Public Health 2011; 39: 7 Suppl., 8–10.
https://doi.org/10.1183/23120541.00138-2017 8
ASTHMA | L. ZIERAU ET AL.
